Literature DB >> 16474073

Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.

William E Collins1, John W Barnwell, Joann S Sullivan, Douglas Nace, Tyrone Williams, Amy Bounngaseng, Jacquelin Roberts, Elizabeth Strobert, Harold McClure, Allan Saul, Carole A Long.   

Abstract

Macaca mulatta monkeys were immunized with the candidate transmission-blocking vaccine against Plasmodium vivax, Pvs25, combined with alum or Montanide ISA 720. Efficacy was measured by combining post-immunization sera with gametocytes obtained from infections induced in chimpanzees using membrane-feeding techniques. The results indicate that immunization of M. mulatta monkeys with Pvs25 and Montanide ISA 720 was more effective than with alum in efficacy and resulted in the maintenance of a lasting transmission-blocking immunity to P. vivax. This was evident two weeks after the second immunization, and more strongly demonstrable 62 and 152 days after the second immunization. This transmission-blocking activity was strongly reinforced by a third immunization given 181 days after the primary immunization, as measured three weeks later by indirect membrane feeding. The use of gametocytes of P. vivax derived from infections induced in chimpanzees can contribute to the selection of appropriate constructs, formulations, and immunization regimens for the development of effective transmission-blocking vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474073

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

Review 1.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Eduardo Solano; Juan Sebastián Ramírez; Carole A Long; Giampietro Corradin; Sócrates Herrera
Journal:  Vaccine       Date:  2021-11-19       Impact factor: 3.641

Review 3.  Acquired immunity to malaria.

Authors:  Denise L Doolan; Carlota Dobaño; J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

4.  Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes.

Authors:  Myriam Arévalo-Herrera; Andrés F Vallejo; Kelly Rubiano; Yezid Solarte; Catherin Marin; Angélica Castellanos; Nora Céspedes; Sócrates Herrera
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

5.  Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.

Authors:  A M Blagborough; K Musiychuk; H Bi; R M Jones; J A Chichester; S Streatfield; K A Sala; S E Zakutansky; L M Upton; R E Sinden; I Brian; S Biswas; J Sattabonkot; V Yusibov
Journal:  Vaccine       Date:  2016-05-10       Impact factor: 3.641

Review 6.  Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.

Authors:  Roos M de Jong; Surafel K Tebeje; Lisette Meerstein-Kessel; Fitsum G Tadesse; Matthijs M Jore; Will Stone; Teun Bousema
Journal:  Immunol Rev       Date:  2019-12-16       Impact factor: 12.988

Review 7.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

8.  A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.

Authors:  Debabani Roy Chowdhury; Evelina Angov; Thomas Kariuki; Nirbhay Kumar
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

9.  A review of adjuvants for Leishmania vaccine candidates.

Authors:  Joshua M Mutiso; John C Macharia; Michael M Gicheru
Journal:  J Biomed Res       Date:  2010-01

10.  Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.

Authors:  Kazutoyo Miura; David B Keister; Olga V Muratova; Jetsumon Sattabongkot; Carole A Long; Allan Saul
Journal:  Malar J       Date:  2007-08-08       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.